NasdaqGS:CYTKBiotechs
The Bull Case For Cytokinetics (CYTK) Could Change Following MYQORZO Progress And HCM Advocacy Grants
Cytokinetics recently announced recipients of its eighth annual Communications Grant Program, awarding two grants to hypertrophic cardiomyopathy patient advocacy groups to expand education and awareness, alongside confirming that MYQORZO (aficamten) is approved for symptomatic obstructive HCM and under marketing review in the European Union.
This combination of regulatory progress for MYQORZO and direct support for HCM community outreach highlights how the company is tying its commercial...